P1012919 nicotine pouch
OtherP1012919, a nicotine pouch with 12 mg of nicotine
NCT Number: NCT05184920
The purpose of this Actual Use Study (AUS) is to investigate how U.S. adult tobacco consumers 21-60 years of age) who are regular smokers (≥5 cigarettes/day) on at least 20 days out of the past 30 days will use P10 and P13 nicotine pouches (Study Investigational Product [IP]) over a 6-week Actual Use Period (AUP) in their real-life/naturalistic environment and in the context of typical consumer marketing materials. Subjects will self-report their ad libitum use of the Study IP as well as use of combustible cigarette (CC) and any other tobacco- or nicotine-containing product (TNP) on a daily basis using an electronic diary (eDiary). The study design is planned to address topics that FDA's Center for Tobacco Products (CTP) has identified as useful in evaluating new tobacco products.
Looking for future studies?
Notify Me21 year–60 year
All sexes
Observational
Schlesinger Phoenix, Phoenix, Arizona, United States
The AUS is a multi-site, open-label, 8-week, prospective observational study, conducted at multiple sites geographically dispersed within the U.S.
Adult smokers will be recruited, and candidate subjects who meet study inclusion criteria and none of the exclusion criteria will give verbal consent for further screening. Candidate subjects will be scheduled to attend an in-person Site Enrollment Visit (SEV).
At the SEV, site staff will confirm eligibility, including age verification with a government-issued photo identification. Candidate subjects will review product information and will be shown physical examples of the Study IP, but will not sample the products. Those who indicate an "intention to use" the Study IP will undergo a second consent process, will be enrolled in the study, and will install and be trained on an eDiary application on their personal smartphones or site provisioned devices.
During a 1-week Baseline Assessment Period (BAP, Week 0), enrolled subjects will record all CC and any other TNP use in the eDiary. At the end of the BAP, subjects will return to the study site for Site Visit 1 (SV1). At this visit, subjects will be able to select up to five different Study IPs for the first two weeks of the AUP from the Study IPs available.
During the subsequent 6-week observational AUP, subjects can choose to use the Study IP (or not). Subjects will be instructed to record all daily Study IP, TNP and CC use in the eDiary. They will return to the site every two weeks during the AUP for an in-person interview to answer questionnaires and for product accountability and resupply. As with SV1, at Site Visit 2 (SV2) and Site Visit 3 (SV3), subjects will be able to select up to five IP varieties (if desired) for use during the subsequent 2-week AUP. After Week 6 of the AUP, there will be a final site visit (SV4) and week-long Close Out Period (COP).
In addition to collecting information on daily ad libitum use of Study IP, TNP and CC use, the study will assess subjective measures (i.e., product assessment) for each Study IP, including product use behaviors and intent to use again (at close of study). Information on intention to quit CC will be collected at enrollment and at study conclusion. A passive surveillance mechanism will be used to collect information on adverse health experiences.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
P1012919, a nicotine pouch with 12 mg of nicotine
P1012915, a nicotine pouch with 8 mg of nicotine
P1012914, a nicotine pouch with 4 mg of nicotine
P1013315, a nicotine pouch with 8 mg of nicotine
P1013119, a nicotine pouch with 12 mg of nicotine
P1013218, a nicotine pouch with 10 mg of nicotine
P1012818, a nicotine pouch with 10 mg of nicotine
P1312915, a nicotine pouch with 8 mg of nicotine
P1312914, a nicotine pouch with 4 mg of nicotine
P1313015, a nicotine pouch with 8 mg of nicotine
P1313314, a nicotine pouch with 4 mg of nicotine
P1312815, a nicotine pouch with 8 mg of nicotine
Time frame: 6 weeks
Number and proportion of subjects who meet the definition of "established users" of the Study IP
Time frame: 8 weeks
Number and proportion of subjects among "established users" who reduce their CPD consumption by at least 50%
Time frame: 8 weeks
Descriptive weekly average CPD consumption per subject among all subjects who complete the study, including both established and non-established users of the Study IP
RAI Services Company
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03259360
Behavior, Chemically-Induced Disorders
San Francisco, California, United States
View Trial DetailsNCT05599451
Behavior, Smoking
Belfast, United Kingdom
View Trial DetailsNCT05363254
Behavior, Smoking
Stockbridge, Georgia, United States
View Trial DetailsNCT05129657
Behavior, Smoking
Raleigh, North Carolina, United States
View Trial Details